An interventional study of Colonoscopy with CADDIE and Standard Colonoscopy in Colorectal Cancer, Polyp of Colon and Adenoma Colon, sponsored by Odin Medical. Completed at 8 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Odin Medical (part of Olympus Corporation) · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 429 studies in Colorectal Neoplasms with a site in Italy — 103 open to participants now, 143 under way, 18 of them phase 3. Colorectal Neoplasms · Italy.
Among the 429 studies in Colorectal Neoplasms with a site in Italy, this one is the 32nd largest by enrollment of the 329 interventional ones that give a count, is one of 25 that started in 2023, is one of 54 with no phase, and was the 328th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →103 of the 429 studies in Colorectal Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
Azienda USL Reggio Emilia - IRCCS · Sites in Italy
Ages 18+
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis · Sites in Italy
Ages 18+
Blue Earth Diagnostics · Sites in Italy, Netherlands
Ages 18–79
EMD Serono Research & Development Institute, Inc. · Sites in Italy, United States, Argentina and 16 more countries
Ages 18+
Gruppo Oncologico Italia Meridionale · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
429 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 81 · Phase 2 155 · Phase 3 81 · Phase 4 3
First in 1988; this study’s year is marked. 25 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 985 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 215 across the 329 interventional studies, 258 across the 96 observational. Of the 228 that completed or were terminated, 99 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
213 of 429 have an industry lead sponsor. The 10 most frequent:
This study is registered under Odin Medical, one of the names counted as Olympus Corporation. Under that name alone:
This is the only study on the registry with Odin Medical as lead sponsor.
Olympus Corporation has 2 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
42 of the studies in Colorectal Neoplasms with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07792109Fondazione Policlinico Universitario Agostino Gemelli IRCCSImplementation Of A Telesurgery Program At A Referral Center For Robotic Surgery | 2026-11-30 |
| NCT02919644Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSVaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer. | 2026-12 |
| NCT05789069HiFiBiO TherapeuticsA Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | 2026-12 |
| NCT05205330Rottapharm BiotechVorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers | 2026-12 |
| NCT07116668SafeHeal IncSafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study | 2026-12 |
Add all 42 to your calendar (.ics) → With an account.
Among the 429 studies in Colorectal Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The EAGLE study is a prospective randomized controlled multicenter parallel design trial, for the assessment of clinical performance of the CADDIE device and to confirm that the device performs as expected.
The EAGLE study will be conducted with a parallel design. Patients who meet the study inclusion/exclusion criteria will be randomized in a 1:1 ratio to receive either computer-aided colonoscopy (CADDIE Arm) using CADDIE or standard colonoscopy without CADe (Control Arm). All resected polyps will be submitted for histologic examination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CADDIE is a computer-assisted detection (CADe) device used in conjunction with endoscopy for the detection of abnormal lesions in the gastrointestinal tract.
Device: Colonoscopy with CADDIE
Patients will receive a standard colonoscopy
Procedure: Standard Colonoscopy
A standard colonoscopy is performed with real-time support of the computer-aided detection (CADe) device CADDIE, used to assist the endoscopist in the detection of colorectal lesions.
Also known as: Colonoscopy
A standard colonoscopy performed without the assistance of any computer-aided detection (CADe) system. Lesion detection relied solely on the endoscopist's visual assessment and clinical judgment.
Adenoma Per Colonoscopy (APC)
The total number of histologically confirmed adenomas and adenocarcinomas divided by the total number of procedures performed.
Time frame: During the procedure
Positive Percent Agreement (PPA)
The percent of histologically confirmed adenomas, sessile serrated adenomas and large (\>10mm) hyperplastic polyps of the proximal colon (cecum, ascending colon, hepatic flexure, and transverse colon) out of total number of resections.
Time frame: During the procedure
Adenoma Detection Rate (ADR)
The percentage of examinations with at least one histologically confirmed adenoma or adenocarcinoma divided by total number of procedures performed.
Time frame: During procedure
Sessile Serrated Adenomas Per Colonoscopy (SSAPC)
Total number of histologically confirmed sessile serrated adenomas, traditional serrated adenomas, or serrated lesion with cytological dysplasia, excluding hyperplastic polyps, divided by the total number of procedures performed.
Time frame: During procedure
Sessile Serrated Adenomas Per Colonoscopy* (SSAPC*)
Total number of histologically confirmed sessile serrated adenomas, with or without cytological dysplasia, divided by the total number of procedures performed.
Time frame: During procedure
Neoplastic Polyps Per Colonoscopy (NPPC)
Total number of histologically confirmed adenomas, adenocarcinomas, sessile serrated adenomas, and traditional serrated adenomas divided by the total number of procedures performed.
Time frame: During procedure
Large Polyps Per Colonoscopy (PPC)
The total number of histologically confirmed polyps ≥ 10 mm detected (adenomas, adenocarcinomas, sessile serrated adenoma, traditional serrated adenoma, hyperplastic), divided by the total number of colonoscopies.
Time frame: During procedure
Large Adenoma Per Colonoscopy
The total number of histologically confirmed ≥ 10 mm adenomas and adenocarcinomas divided by the total number of colonoscopies.
Time frame: During the procedure
Colonoscope Withdrawal Time of Negative Procedures
The time it takes to withdraw the colonoscope from the furthest point (TI or caecum) for colonoscopies that did not require any biopsies or resections.
Time frame: During procedure
Colonoscope Withdrawal Time
The time it takes to withdraw the colonoscope from the furthest point (TI or cecum) back to the rectum, including biopsy
Time frame: During procedure
985 patients gave informed consent: 946 patients planned and an additional 39 were recruited to replace patients who did not undergo a colonoscopy procedure, high-risk FIT+ patients, or procedures which used an equipment not cleared for use in the US. 973 patients were randomized (Safety population). 934 eligible patients underwent a complete procedure (ITT). 841 patients reflective of the device's intended use were included in primary analysis (mITT)
| Milestone | CADDIE Colonoscopy (CADDIE Arm) | Standard High-definition White-light Colonoscopy (SoC Arm) |
|---|---|---|
| Started | 478 | 495 |
| Completed | 461 | 473 |
| Not completed | 17 | 22 |
The total number of histologically confirmed adenomas and adenocarcinomas divided by the total number of procedures performed.
| Colonoscopies | CADDIE Colonoscopy (CADDIE Arm) | Standard Colonoscopy (Control Arm) |
|---|---|---|
| Adenoma Per Colonoscopy (APC) | 0.82 ± 1.40 | 0.62 ± 1.19 |
The percent of histologically confirmed adenomas, sessile serrated adenomas and large (\>10mm) hyperplastic polyps of the proximal colon (cecum, ascending colon, hepatic flexure, and transverse colon) out of total number of resections.
| Polyps | CADDIE Colonoscopy (CADDIE Arm) | Standard Colonoscopy (Control Arm) |
|---|---|---|
| Positive Percent Agreement (PPA) | 377 | 276 |
The percentage of examinations with at least one histologically confirmed adenoma or adenocarcinoma divided by total number of procedures performed.
| Colonoscopies | CADDIE Colonoscopy (CADDIE Arm) | Standard Colonoscopy (Control Arm) |
|---|---|---|
| Adenoma Detection Rate (ADR) | 180 (0 to 0) | 152 (0 to 0) |
Total number of histologically confirmed sessile serrated adenomas, traditional serrated adenomas, or serrated lesion with cytological dysplasia, excluding hyperplastic polyps, divided by the total number of procedures performed.
| Sessile Serrated Adenoma | CADDIE Colonoscopy (CADDIE Arm) | Standard Colonoscopy (Control Arm) |
|---|---|---|
| Sessile Serrated Adenomas Per Colonoscopy (SSAPC) | 0.09 ± 0.46 | 0.04 ± 0.21 |
Total number of histologically confirmed sessile serrated adenomas, with or without cytological dysplasia, divided by the total number of procedures performed.
| Sessile Serrated Adenoma | CADDIE Colonoscopy (CADDIE Arm) | Standard Colonoscopy (Control Arm) |
|---|---|---|
| Sessile Serrated Adenomas Per Colonoscopy* (SSAPC*) | 0.08 ± 0.45 | 0.03 ± 0.16 |
Total number of histologically confirmed adenomas, adenocarcinomas, sessile serrated adenomas, and traditional serrated adenomas divided by the total number of procedures performed.
| Adenoma | CADDIE Colonoscopy (CADDIE Arm) | Standard Colonoscopy (Control Arm) |
|---|---|---|
| Neoplastic Polyps Per Colonoscopy (NPPC) | 0.91 ± 1.48 | 0.66 ± 1.20 |
The total number of histologically confirmed polyps ≥ 10 mm detected (adenomas, adenocarcinomas, sessile serrated adenoma, traditional serrated adenoma, hyperplastic), divided by the total number of colonoscopies.
| Large polyps | CADDIE Colonoscopy (CADDIE Arm) | Standard Colonoscopy (Control Arm) |
|---|---|---|
| Large Polyps Per Colonoscopy (PPC) | 0.12 ± 0.44 | 0.05 ± 0.24 |
The total number of histologically confirmed ≥ 10 mm adenomas and adenocarcinomas divided by the total number of colonoscopies.
| Confirmed adenomas | CADDIE Colonoscopy (CADDIE Arm) | Standard Colonoscopy (Control Arm) |
|---|---|---|
| Large Adenoma Per Colonoscopy | 0.09 ± 0.36 | 0.04 ± 0.23 |
The time it takes to withdraw the colonoscope from the furthest point (TI or caecum) for colonoscopies that did not require any biopsies or resections.
| Minutes | CADDIE Colonoscopy (CADDIE Arm) | Standard Colonoscopy (Control Arm) |
|---|---|---|
| Colonoscope Withdrawal Time of Negative Procedures | 8 (7 to 11) | 8 (7 to 10) |
The time it takes to withdraw the colonoscope from the furthest point (TI or cecum) back to the rectum, including biopsy
| Minutes | CADDIE Colonoscopy (CADDIE Arm) | Standard Colonoscopy (Control Arm) |
|---|---|---|
| Colonoscope Withdrawal Time | 11 (8 to 15) | 10 (8 to 13) |
Collected over From the start of the procedure up to the follow-up phone call (24 hours post-procedure). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CADDIE Colonoscopy (CADDIE Arm) | 0/478 (0%) | 0/478 (0%) | 2/478 (0.4%) |
| Standard Colonoscopy (Control Arm) | 0/495 (0%) | 0/495 (0%) | 3/495 (0.6%) |
| Event | CADDIE Colonoscopy (CADDIE Arm) | Standard Colonoscopy (Control Arm) |
|---|---|---|
| Abdominal pain related to the procedure,Gastrointestinal disorders | 1/478 | 2/495 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/478 | 0/495 |
| Nausea possibly related to the procedureGastrointestinal disorders | 0/478 | 1/495 |
985 patients gave informed consent: A total of 946 patients were planned, and an additional 39 were recruited to replace patients who did not undergo a colonoscopy procedure, symptomatic FIT+ patients, and procedures which used an endoscope not cleared. 934 eligible patients completed a screening or surveillance colonoscopy.
| Age, Continuous(Year) | CADDIE Colonoscopy (CADDIE Arm) | Standard Colonoscopy (Control Arm) | Total |
|---|---|---|---|
| Mean | 58.7 ± 9.0 | 58.2 ± 9.5 | 58.5 ± 9.3 |
| Sex: Female, Male(Participants) | CADDIE Colonoscopy (CADDIE Arm) | Standard Colonoscopy (Control Arm) | Total |
|---|---|---|---|
| Female | 194 | 218 | 412 |
| Male | 223 | 206 | 429 |
| Race (NIH/OMB)(Participants) | CADDIE Colonoscopy (CADDIE Arm) | Standard Colonoscopy (Control Arm) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 414 | 423 | 837 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 0 | 3 |
| Ethnicity (NIH/OMB)(Participants) | CADDIE Colonoscopy (CADDIE Arm) | Standard Colonoscopy (Control Arm) | Total |
|---|---|---|---|
| Hispanic or Latino | 75 | 66 | 141 |
| Not Hispanic or Latino | 337 | 349 | 686 |
| Unknown or Not Reported | 5 | 9 | 14 |
| Colonoscopy indication(partecipants) | CADDIE Colonoscopy (CADDIE Arm) | Standard Colonoscopy (Control Arm) | Total |
|---|---|---|---|
| Screening colonoscopy | 324 | 329 | 653 |
| Surveillance colonoscopy | 93 | 95 | 188 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2023 to primary completion in Nov 2023, 6 months.
Results were first posted in Oct 2026, 2 years 11 months after primary completion.
Of 58 industry-sponsored interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 37. This study's 6 months is below that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.